Vinge advises Swegon in UK acquisition

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.

Vinge has advised IK Partners in connection with the acquisition of Selatek

Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.